) oscillations are indispensable for nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) activation and downstream gene transcription driving osteoclastogenesis during skeletal remodeling and pathological bone loss. Here we describe, to our knowledge, the first known function of transmembrane protein 178 (Tmem178), a PLCγ2 downstream target gene, as a critical modulator of the NFATc1 axis. In surprising contrast to the osteopetrotic phenotype of PLCγ2 −/− mice, Tmem178 −/− mice are osteopenic in basal conditions and are more susceptible to inflammatory bone loss, owing to enhanced osteoclast formation. Mechanistically, Tmem178 localizes to the ER membrane and regulates RANKL-induced Ca 2+ fluxes, thus controlling NFATc1 induction. Importantly, down-regulation of Tmem178 is observed in human CD14 + monocytes exposed to plasma from systemic juvenile idiopathic arthritis patients. Similar to the mouse model, reduced Tmem178 expression in human cells correlates with excessive osteoclastogenesis. In sum, these findings identify an essential role for Tmem178 to maintain skeletal mass and limit pathological bone loss.
Tmem178 | osteoclasts | NFATc1 | calcium | sJIA I n recent years, the skeleton has been appreciated as a dynamic system that, in addition to serving its evident mechanical functions, cross-talks with the endocrine, nervous, immune, reproductive, and digestive systems. Skeletal fragility is observed in inflammatory, endocrine, and metabolic disorders (1, 2) . Perhaps the most studied inflammatory condition associated with dysregulated bone homeostasis is rheumatoid arthritis (RA). Elevated levels of inflammatory cytokines acting in concert with the osteoclastogenic factor, receptor activator of NF-κB ligand (RANKL), drive excessive osteoclast (OC) differentiation, and lead to local joint erosion and systemic bone loss (3, 4) . Pathological bone loss is also observed in children with systemic juvenile idiopathic arthritis (sJIA); low bone mass and high risk fragility fractures often persist in adults who suffered from sJIA during childhood (5) . Unfortunately, current therapeutics are not always successful in suppressing both the inflammatory and resorptive components of arthritic diseases, and many patients suffer progressive and irreversible joint damage even without active system disease.
OC differentiation is initiated by the binding of RANKL to its receptor RANK on the mononuclear precursors (3, 4) . Downstream of RANK signaling cascades, the nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) is required for osteoclastogenesis and directly regulates many genes important for OC differentiation and function (6) (7) (8) (9) (10) . NFATc1 activation is primarily regulated by calcium (Ca 2+ ). RANK signaling activates the catalytic activity of phospholipase C gamma-2 (PLCγ2) to generate the second messengers inositol-1,4,5-triphosphate (IP 3 ) and diacylglycerol (11 /calmodulin-dependent pathway of NFATc1 nuclear translocation to drive osteoclastogenesis (13) . Targeted deletion of PLCγ2 in mice results in osteopetrosis due to insufficient NFATc1 expression. Similarly, genetic or pharmacological interference of ER or plasma membrane Ca 2+ channel activity blocks osteoclastogenesis in vitro and in vivo by impairing NFATc1 expression (14) (15) (16) (17) (18) (19) . Differently from T cells, however, NFATc1 activation must be sustained throughout osteoclastogenesis over the course of days and depends on both amplitude and duration of the Ca 2+ fluxes. For this reason, Ca + mobilization must be finely controlled by regulatory proteins that potentiate or suppress Ca 2+ transport (20, 21) . However, such modulatory proteins in primary OCs are largely uncharacterized.
In this study, we report that Tmem178 is a novel PLCγ2-dependent protein that controls Ca 2+ fluxes in the OC. In contrast to the proosteoclastogenic role of PLCγ2, however, Tmem178 negatively regulates osteoclastogenesis in vitro and in vivo. Mechanistically, Tmem178 deficiency enhances RANKL-induced Ca 2+ oscillations, thereby increasing NFATc1 levels and osteoclastogenesis. Further highlighting the clinical relevance of our findings, human monocytes treated with plasma from sJIA patients down-regulate Tmem178 and undergo more robust Significance Excessive osteoclast (OC) activation and joint erosion are often observed in arthritis patients, including children suffering from systemic juvenile idiopathic arthritis (sJIA), even in the absence of active systemic symptoms. Herein, we identify a previously uncharacterized protein, transmembrane protein 178 (Tmem178), as a novel downstream target of the receptor activator of NF-κB ligand/phospholipase C gamma-2 signaling axis in the OC. Surprisingly, Tmem178 functions as a negative regulator of OC differentiation in basal and inflammatory conditions by controlling NFATc1 induction via modulation of Ca 2+ fluxes. Importantly, Tmem178 is dysregulated in the context of sJIA, where defective Tmem178 expression is associated with enhanced OC differentiation and erosive disease. These findings represent a novel mechanism of negative feedback that limits osteoclastogenesis and consequent resorptive activity to maintain skeletal integrity.
osteoclastogenesis, suggesting that Tmem178 may be a modulator of disease-associated bone erosion.
Results
Tmem178 Deletion Decreases Bone Mass in Basal Conditions. We have reported that ablation of PLCγ2 results in a blockade of osteoclastogenesis owing to defective NFATc1 induction (11, 22) . PLCγ2-deficient mice are osteopetrotic and are also protected from inflammatory osteolysis (23, 24) . Therefore, we sought to identify novel PLCγ2-dependent signaling mediators that could inform therapeutic design for disorders caused by OC overactivity, such as osteoporosis and RA. We performed a gene array comparing adherent wild-type (WT) and PLCγ2-deficient OC precursors and found that Tmem178 was highly expressed in WT cells, but not in cells lacking PLCγ2 (Fig. S1A) .
Tmem178 is a previously unstudied multipass integral membrane protein. Despite its name, Tmem178 does not share any structural domains or homology with other "Tmem" proteins. We began by assessing Tmem178 expression in whole tissues from WT and PLCγ2
−/− mice. Strikingly, Tmem178 is highly expressed in WT whole bone, whereas transcript levels are low in other tissues including spleen, liver, thymus, and testes (Fig. 1A) . Confirming the gene array data, Tmem178 expression strongly depends on PLCγ2. Thus, we hypothesized that Tmem178 is a downstream target controlling PLCγ2's effects on bone homeostasis.
To establish the physiological importance of Tmem178, we examined the bone phenotype of Tmem178-null mice. We expected Tmem178 −/− mice to mirror the osteopetrotic phenotype of PLCγ2 −/− mice. Surprisingly, 16-wk-old female Tmem178 −/− mice display a 35% decrease in trabecular bone volume with significant trabecular thinning compared with WT littermates (Fig. 1 B-D) . Tartrate-resistant acid phosphatase (TRAP) staining of long bone sections reveals a significant increase in OC surface normalized to bone surface in Tmem178 −/− mice ( Fig. 1 E and F) , wheres osteoblast (OB) numbers are equivalent between genotypes (Fig. S1B) . Accordingly, mineral apposition rate (MAR), bone formation rate (BFR), and RANKL and OPG mRNA levels in whole bones flushed of marrow cells are similar in the two genotypes (Fig. S1 C-G). These in vivo data suggest that Tmem178 suppresses OC differentiation via an unexpected negative feedback loop downstream of PLCγ2.
Tmem178 Expression Depends on PLCγ2/NFATc1 Signaling. Because the in vivo data suggested OC-intrinsic effects, we examined Tmem178 expression in OC lineage cells in vitro. Tmem178 mRNA increases during osteoclastogenesis and depends on PLCγ2 ( Fig. 2A) . A similar extent of Tmem178 induction is observed in human CD14
+ monocytes treated with RANKL compared with M-CSF alone (Fig. 2B) . In contrast to the OCs, Tmem178 is not significantly expressed in the OBs (Fig. S1H) , confirming the observation that Tmem178 deletion does not affect bone formation.
Because NFATc1 is downstream of PLCγ2, and the Tmem178 promoter harbors NFAT consensus binding sites (rvista.dcode. org), we examined Tmem178 expression in NFATc1-deficient cells. We found that RANKL-induced Tmem178 up-regulation is blunted in NFATc1-null cells compared with controls (Fig. S1I) . In addition to NFAT, PLCγ2 controls the classical NF-κB pathway following RANKL and integrin-mediated adhesion. We found that Tmem178 expression is induced by adhesion, and this increase partially depends on the classical NF-κB subunit p65 (Fig. S1J ). These data position Tmem178 directly downstream of the RANKL/PLCγ2 axis in the OC. . Altogether these findings demonstrate that Tmem178 is a negative regulator of OC differentiation but does not exert a direct effect on the cell's resorptive capacity.
Tmem178 Deficiency Enhances Ca
2+ Fluxes in OCs. To understand how Tmem178 modulates OC differentiation, we assessed activation of RANKL-induced NF-κB and MAPKs. We find no perceptible differences in NF-κB and MAPK activation between WT and Tmem178 −/− BMMs (Top) or preOCs (Bottom) (Fig. S3A ). Similarly, M-CSF induction of p-AKT and p-ERK is equivalent in both genotypes (Fig. S3B) .
Because RANK signaling to PLCγ2 activates Ca 2+ fluxes that are indispensable for osteoclastogenesis, we measured intracellular Ca 2+ levels in single cells by ratiometric imaging. Cells were cultured with M-CSF and RANKL for 24 h (preOCs) before loading with Fura-2AM and imaging. Tmem178
−/− preOCs consistently show higher levels of intracellular Ca 2+ with fluxes of greater amplitude compared with WT ( Fig. 3 A (Fig. 3C ). This effect is not due to a change in total ER Ca 2+ content, because ionomycin-induced ER Ca 2+ emptying is similar in Tmem178-expressing cells versus controls (Fig. S4A) . Tmem178 Resides in the ER and Binds to Stim1. Supporting our findings that Tmem178 acts on ER Ca 2+ mobilization, we determined by immunofluorescence that Tmem178 localizes to the ER but not the plasma membrane in mature OCs (Fig. 3D) . Next, we wanted to know whether Tmem178 interacts with known ER-resident proteins involved in Ca 2+ mobilization. Inositol triphosphate receptors (IP3Rs) are ER-resident Ca 2+ channels, which facilitate ER Ca 2+ release and consequent intracellular Ca 2+ fluxes in response to IP3 generated by PLCγ signaling. IP3R isoforms 1, 2, and 3 are expressed in the OC, and IP3R2 and IP3R3 modulate RANKL-stimulated Ca 2+ fluxes (14) . However, by coimmunoprecipitation, we did not detect an interaction between Tmem178 and any IP3R isoform (Fig. S4B) .
Next we considered the protein Stim1, which is an ER Ca 2+ sensor controlling Ca 2+ fluxes during osteoclastogenesis (16, 17, 25) . We expressed Tmem178-HA and Stim1-Myc in HEK293T cells and found that Tmem178 and Stim1 interact in resting conditions (control), and to a less extent in the presence of Tg and Tg + 1.8 mM Ca 2+ (Fig. 3E) . Using confocal microscopy, we confirmed Tmem178/Stim1 interaction in BMMs treated with RANKL for 24 h (Fig. S4C) . Although Stim1 bears significant homology to the related protein Stim2, we did not detect an interaction between Tmem178 and Stim2 (Fig. S4D) .
Because Stim1 binds to Orai1 to activate SOCE, we coexpressed Tmem178, Stim1, and Orai1 in HEK293T cells. We found no interaction between Tmem178 and Orai1, nor did we find that the presence or absence of Tmem178 affects Stim1 coupling to Orai1 (Fig. 3 E and F cultures show heightened NFATc1 transcript levels throughout osteoclastogenesis (Fig. 4A) and a higher percentage of cells with NFATc1 nuclear staining (Fig. 4B and Fig. S5A ). Consistent with increased NFATc1 nuclear levels, we observed an earlier and greater magnitude of induction of NFATc1 target genes including TRAP (Acp5), Cathepsin K (CtsK), and calcitonin receptor (Calcr) (Fig. 4C ). Cytoplasmic and nuclear fractionation of RANKLtreated cells also illustrates earlier and sustained NFATc1 nuclear 
translocation in Tmem178
−/− OCs compared with WT ( Fig. 4D  and Fig. S5B ).
To determine whether Tmem178 suppresses osteoclastogenesis by limiting NFATc1 levels, we ectopically expressed Tmem178 in WT BMMs and analyzed their ability to induce NFATc1 and undergo OC differentiation. Tmem178 expression attenuates NFATc1 transcripts and reduces NFATc1 nuclear translocation in response to RANKL (Fig. 4 E and F and Fig. S5C) , with a resulting reduction in osteoclastogenesis (Fig. 4 G and H) . Altogether, these data indicate that Tmem178 acts in a negative feedback loop to restrain further NFATc1 activation and OC differentiation.
Tmem178
−/− Mice Suffer Profound Inflammatory Osteolysis. Next, we wondered whether Tmem178 similarly regulates OC formation driven by inflammatory cytokines. Addition of TNF-α or LPS further exacerbates Tmem178 −/− OC differentiation in vitro (Fig.  5A ). Most importantly, Tmem178 −/− mice injected with LPS over the calvaria develop profound focal osteolysis (Fig. 5 B and C) , and increased OC surface compared with WT ( Fig. 5D and Fig. S6A ).
To determine whether Tmem178 could modulate bone loss in a model of inflammatory arthritis, WT and Tmem178 −/− mice were injected with arthritogenic serum from K/BxN mice. Both genotypes develop an equivalent inflammatory response, measured by paw thickness (Fig. S6B) . However, Tmem178
−/− mice suffer significantly more bone loss, measured by remaining bone volume at the knee by microCT (Fig. 5 E and F) , driven by a significant increase in OC differentiation (Fig. 5G ). Altogether these data indicate that Tmem178 restrains inflammatory bone loss.
Tmem178 Is Down-Regulated in Human Monocytes Exposed to sJIA Plasma. Based on the above observations, we wondered whether changes in Tmem178 levels would be detected in patients affected by inflammatory bone loss, such as sJIA. Seminal studies of sJIA pathogenesis proved that circulating factors present in the plasma of patients are sufficient to drive the disease phenotype even in healthy monocytes (26, 27) . We cultured CD14 + monocytes from healthy donors with M-CSF and RANKL for 2 d to generate preOCs and then added the plasma collected from healthy controls (HC) (n = 10) or sJIA patients (n = 20). Strikingly, Tmem178 transcript is significantly reduced in CD14 + cells treated with sJIA plasma compared with HC plasma (Fig.  5H ). The addition of sJIA plasma potently augments OC differentiation (Fig. 5 I and J) . Notably, Tmem178 expression is further blunted, whereas OC numbers are significantly increased, following exposure to plasma from five patients with erosive disease (Fig. 5 I and J) . Finally, we tested the ability of sJIA plasma to affect osteoclastogenesis in murine cells expressing ectopic Tmem178 or control pMX empty vector. As expected, osteoclastogenesis is enhanced in pMX cells treated with sJIA plasma compared with HC plasma (Fig. 5K) . Most importantly, ectopic expression of Tmem178 in cells exposed to sJIA plasma is sufficient to overcome excessive OC differentiation, returning to the HC baseline. Taken together, these data indicate that defective Tmem178 expression may drive excessive osteoclastogenesis and contribute to erosive disease in sJIA.
Discussion
As the sole bone-resorbing cell in the body, the OC must be carefully regulated to allow for healthy skeletal remodeling, respond to physiological stress, and return to homeostasis. Activation and termination of the signaling pathways underlying the formation of mature OCs from mononuclear precursors is a critical checkpoint of control. Here we identify a role for Tmem178 as a previously identified target of the RANKL/PLCγ2 pathway; in turn, Tmem178 acts in a negative feedback loop to restrain NFATc1 and excessive OC differentiation in mice and humans. This work expands the understanding of cell-intrinsic negative feedback mechanisms that are necessary to maintain healthy bone and identifies Tmem178 as a new negative regulator of RANKLinduced Ca 2+ fluxes. Because of the importance of Ca 2+ amplitude and duration in discriminating between different response pathways, cytoplasmic Ca 2+ levels are tightly regulated. Regulators of Ca 2+ channel activity in the OC have only recently come under investigation. Ong et al. described the importance of transient receptor potential cation channel 1 in SOCE activation during OC formation (28) . Similarly, Tmem64 (no homology to Tmem178) promotes RANKL-induced Ca 2+ oscillations by bolstering the activity of Sarco-Endoplasmic Reticulum ATPase isoform 2, which actively refills ER Ca 2+ stores, and is required for NFATc1 induction and osteoclastogenesis (15, 19, 29) . Whereas these studies demonstrate that the loss of positive regulators of Ca 2+ fluxes perturbs osteoclastogenesis and leads to increased bone mass, we now identify a negative regulator of Ca 2+ fluxes whose ablation leads to up-regulation of NFATc1 levels and an osteopenic phenotype. NFAT proteins show enhanced Ca 2+ sensitivity compared with other transcription factors, enabling NFAT transcription by low Ca 2+ levels (30) . Furthermore, in the OC, differently from other cell types such as T cells, not only the amplitude of Ca 2+ signaling but also the generation of continuous Ca 2+ oscillations in response to RANKL is required for efficient NFATc1 transcriptional activation. We find that following RANKL exposure, Tmem178 −/− cells reach higher intracellular Ca 2+ levels compared with WT, which correlate with greater NFATc1 induction and increased NFATc1 nuclear translocation. Consequently, Tmem178
−/− cells undergo more rapid and robust osteoclastogenesis in vitro and in vivo, and Tmem178 −/− mice develop osteopenia. In contrast, ectopic Tmem178 expression in OC precursors reduces NFATc1 levels and decreases osteoclastogenesis in physiological conditions and following exposure to sJIA plasma.
Stim1 is an ER Ca 2+ sensor expressed in numerous cell types, including OCs, mast cells, B cells, and T cells. Pharmacological inhibition of Stim1 impairs SOCE, thereby blocking osteoclastogenesis (16) . In addition to associating with Orai1 to control SOCE, Stim1 also couples to numerous other Ca 2+ channels, Ca 2+ pumps, ER chaperone proteins, and regulatory adaptor proteins, thereby influencing multiple pathways of Ca 2+ transport (31) . In kidney epithelial cells, Stim1 interacts with polycystin-1, diminishing IP3R-mediated ER Ca 2+ release (32) . In aortic endothelial cells, Stim1 potentiates IP3R-mediated ER Ca 2+ release (33) . In muscle cells, Stim1 inhibits Ca 2+ discharge from the sarcoplasmic reticulum (34)
2+ levels and activating SOCE, but also appears to regulate, at least in part, ER Ca 2+ release in multiple cell types. In the OC, we find that Tmem178 localizes to the ER where it associates with Stim1. Interestingly, Tmem178 does not bind to Orai1 or inhibit Orai1-Stim1 coupling, and Tmem178 does not modulate SOCE. Instead, Tmem178 ectopic expression reduces Tg-mediated ER Ca 2+ release, suggesting that Tmem178 may modulate Stim1's roles independent of SOCE. Further studies are necessary to wholly understand the mechanism of Tmem178-mediated Ca 2+ regulation and the significance of the Tmem178-Stim1 complex during osteoclastogenesis.
Tmem178 interaction with Stim1 is particularly interesting in the context of arthritis. Stim1 single nucleotide polymorphisms (SNPs) were recently identified in patients with ankylosing spondylitis (AS), a chronic inflammatory disease of the spine and joints (36) . These SNPs correlated with significantly higher inflammatory markers including C-reactive protein and in some cases higher circulating levels of TNF-α and IL-6. Although we did not have access to AS patient samples to measure Tmem178 levels or Tmem178/Stim1 binding, we found that reduced Tmem178 expression is associated with augmented osteoclastogenesis in the context of sJIA. Further supporting a role for Tmem178 in inflammatory arthritis, Tmem178
−/− mice suffer profound osteolysis following LPS and in K/BxN arthritis, and in vitro studies show increased responsiveness to TNF-induced osteoclastogenesis. These results strongly indicate that Tmem178 acts in a negative feedback loop to restrain exuberant osteoclastogenesis and regulate bone mass in basal and inflammatory conditions. sJIA is characterized by arthritis and systemic inflammation. Bone erosion and systemic bone loss were observed in up to 50% of children with sJIA in the prebiologic era. Even more recently, CARRAnet registry data (collected since 2010) on 435 children with sJIA show that joint damage remains a significant problem for at least 20% of these patients despite remission of the systemic inflammation. To date, there are no markers that identify the subset of sJIA patients who will develop erosive disease. Further, the diagnosis of sJIA is a clinical diagnosis of exclusion, and unfortunately a delayed diagnosis contributes to the development of erosive changes. We now show that Tmem178 expression is significantly reduced in human CD14 + monocytes exposed to sJIA plasma, whereas OC differentiation is increased. Most importantly, ectopic expression of Tmem178 restrains the increase in OC formation induced by sJIA plasma. Consistent with this result, we observe a significant reduction in Tmem178 levels in samples treated with plasma from sJIA patients with erosive disease, positioning Tmem178 as a potential biomarker for the subset of sJIA patients who will develop erosive disease. These initial findings with a limited number of patient samples necessitate future investigations with larger cohorts of sJIA patients. We also do not yet understand the complex upstream mechanism that regulates Tmem178 expression in response to sJIA plasma. Further investigation into the role of Tmem178 in the pathogenesis of sJIA and other arthritic conditions associated with erosive disease is warranted.
In conclusion, we have identified Tmem178 as a new PLCγ2-dependent gene. Despite its dependence on the RANKL/PLCγ2 pathway, however, Tmem178 acts in a negative feedback loop to restrain NFATc1 up-regulation and OC responses in basal and pathological conditions.
Methods and Materials
Mice. (K) Quantification of OC area from murine BMMs expressing pMX or Tmem178 and treated with HC or sJIA plasma. **P < 0.01.
background maintained by heterozygous breeding. In vitro experiments were repeated with bone marrow from both mice of C57BL/6-129 and C57BL/6 background. Analysis of bone phenotype by microCT and histology was performed as described (37) . All experiments were approved by the Washington University School of Medicine animal care and use committee.
Primary Cell Culture. BMMs were isolated from 6-to 8-wk-old mice as described (11) . To form OCs, BMMs were cultured with 50 ng/mL GST-RANKL and 10 ng/mL M-CSF (osteoclastogenic medium) for 3-5 d. Cells were fixed in 4% (vol/vol) paraformaldehyde in PBS (Polysciences) and stained for TRAP by using the leukocyte acid phosphatase kit (Sigma).
Plasmids and Retrovirus Generation. Human Tmem178 cDNA (clone ID 528607; Open Biosystems) was cloned into the blasticidin-resistant pMX retroviral vector containing an HA tag at the C terminus by using BamHI and XhoI restriction sites. Stim1-Myc and Orai1-FLAG were gifts from Monika Vig, Washington University in St. Louis, St. Louis.
Single-Cell Ca 2+ Measurements. Cells were loaded with 3 μM Fura-2AM (Invitrogen) in phenol red-free DMEM (Invitrogen) containing 10 ng/mL M-CSF for 30 min at room temperature in the dark and imaged immediately in phenol red-free DMEM containing 10 ng/mL M-CSF and 100 ng/mL RANKL. Fura-2 ratios were measured by alternate excitation at 340 nm and 380 nm at a frequency of 1 image pair every 2 s. At least 40 cells per field were analyzed in each replicate.
Human Plasma Preparation and Osteoclastogenesis. All subjects provided informed consent before participating in the study in accordance with the Declaration of Helsinki. Plasma was prepared from whole, anticoagulated blood within 2 h after blood draw. CD14
+ PBMCs were isolated from healthy donor by Ficoll gradient centrifugation followed by positive selection with anti-CD14 magnetic beads (Miltenyi Biotec). For osteoclastogenesis, 15%
plasma by volume was added to CD14 + cells after 2 d of culture with 15 ng/mL hM-CSF and 100 ng/mL GST-RANKL. For Tmem178 mRNA analysis, CD14 + preOCs were incubated with 15% control or patient plasma for 8 h before mRNA extraction.
Study Approval. For all mouse studies, experiments were approved by the Washington University School of Medicine animal care and use committee. Human studies were approved by the Institutional Review Board at Stanford University.
Statistics. All data represent mean ± SD. Data were analyzed by using twotailed Student's t test. Time course experiments were analyzed by using a one-way ANOVA followed by a post hoc Newman- 
